Ubiquitination/ Proteasome


Once the substrate protein is labeled, proteasome will bind to a polyubiquitin chain, allowing the degradation of the labeled protein. The polyubiquitinated target protein is then recognized and degraded by the 26S proteasome. Deubiquitinating enzymes (DUBs) reverse the process of ubiquitination by removing ubiquitin from its substrate protein. Dysregulation of the ubiquitin-proteasome system has been linked to cancer, diabetes, cardiovascular and neurodegenerative diseases etc.
-
BA3888 6RK73Summary: 6RK73 is a covalent irreversible specific inhibitor. -
BA3898 8RK64Summary: 8RK64 is a covalent inhibitor. -
BA3907 LCAHASummary: LCAHA (LCAhydroxyamide), a deubiquitinase inhibitor, was found to be 9.7 μM and 3.7 μM in Ub-AMC analysis and Di-Ub analysis, respectively. -
BA3908 STAMBP-IN-1Summary: STAMBP-IN-1 is a small molecule inhibitor of STAMBP deubiquitinase that interrupts the interaction. -
BA3913 USP7-IN-10Summary: USP7-IN-10 is a potent ubiquitin protein-specific protease 7 inhibitor. -
BA3914 USP7-IN-13Summary: USP7-IN-13 is an inhibitor value of 0.2 to 1 μM. -
BA2731 IberdomideSummary: Iberdomide (CC-220) is an orally effective (CRBN) E3 ligase modulator. -
BA2820 HinokiflavoneSummary: Hinokiflavone, a novel modulator of splicing activity, is effective in vitro and in vivo. -
BA2848 Wu-5Summary: Wu-5 is a USP10 inhibitor. -
BA2868 TZ9Summary: TZ9 is a selective inhibitor.
